BSW Wealth Partners Increases Stock Holdings in Danaher Co. (NYSE:DHR)

BSW Wealth Partners raised its stake in shares of Danaher Co. (NYSE:DHR) by 3.7% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 3,713 shares of the conglomerate’s stock after purchasing an additional 134 shares during the quarter. BSW Wealth Partners’ holdings in Danaher were worth $852,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently modified their holdings of DHR. Wedge Capital Management L L P NC boosted its position in Danaher by 3.2% during the 3rd quarter. Wedge Capital Management L L P NC now owns 1,231 shares of the conglomerate’s stock valued at $342,000 after acquiring an additional 38 shares in the last quarter. Meridian Financial Partners LLC boosted its position in Danaher by 4.4% during the third quarter. Meridian Financial Partners LLC now owns 957 shares of the conglomerate’s stock valued at $266,000 after purchasing an additional 40 shares in the last quarter. Kovack Advisors Inc. grew its stake in Danaher by 3.4% in the third quarter. Kovack Advisors Inc. now owns 1,243 shares of the conglomerate’s stock valued at $346,000 after purchasing an additional 41 shares during the last quarter. Well Done LLC lifted its position in shares of Danaher by 1.2% during the third quarter. Well Done LLC now owns 3,551 shares of the conglomerate’s stock valued at $987,000 after buying an additional 42 shares during the last quarter. Finally, Waypoint Capital Advisors LLC boosted its holdings in shares of Danaher by 0.9% in the 3rd quarter. Waypoint Capital Advisors LLC now owns 4,520 shares of the conglomerate’s stock valued at $1,257,000 after buying an additional 42 shares in the last quarter. 79.05% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

DHR has been the subject of a number of analyst reports. JPMorgan Chase & Co. decreased their target price on shares of Danaher from $310.00 to $300.00 and set an “overweight” rating for the company in a research report on Tuesday. Wolfe Research upgraded Danaher from a “peer perform” rating to an “outperform” rating and set a $285.00 target price on the stock in a research note on Thursday, October 31st. Evercore ISI increased their price target on Danaher from $275.00 to $278.00 and gave the company an “outperform” rating in a research note on Tuesday, October 1st. Robert W. Baird cut their price objective on shares of Danaher from $277.00 to $268.00 and set an “overweight” rating on the stock in a report on Tuesday. Finally, Barclays cut their price target on shares of Danaher from $285.00 to $275.00 and set an “equal weight” rating on the stock in a research note on Wednesday, October 23rd. Six analysts have rated the stock with a hold rating and sixteen have issued a buy rating to the company’s stock. According to MarketBeat, Danaher presently has an average rating of “Moderate Buy” and a consensus price target of $285.81.

Danaher Stock Down 1.1 %

Shares of DHR opened at $247.77 on Wednesday. The company has a current ratio of 1.37, a quick ratio of 1.01 and a debt-to-equity ratio of 0.32. The firm has a market cap of $178.96 billion, a P/E ratio of 47.29, a PEG ratio of 4.43 and a beta of 0.83. The stock’s 50 day moving average is $235.75 and its two-hundred day moving average is $253.65. Danaher Co. has a 12 month low of $225.42 and a 12 month high of $281.70.

Danaher Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, January 31st. Shareholders of record on Friday, December 27th will be issued a dividend of $0.27 per share. The ex-dividend date of this dividend is Friday, December 27th. This represents a $1.08 dividend on an annualized basis and a dividend yield of 0.44%. Danaher’s payout ratio is currently 20.61%.

Danaher Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.